Dimensional Fund Advisors LP Boosts Stock Position in Sight Sciences, Inc. (NASDAQ:SGHT)

Dimensional Fund Advisors LP boosted its position in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 79.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 243,954 shares of the company's stock after acquiring an additional 108,001 shares during the period. Dimensional Fund Advisors LP owned 0.48% of Sight Sciences worth $887,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. KCK LTD. bought a new position in shares of Sight Sciences in the fourth quarter valued at approximately $15,925,000. Renaissance Technologies LLC lifted its holdings in shares of Sight Sciences by 654.3% in the fourth quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock valued at $1,431,000 after purchasing an additional 340,906 shares in the last quarter. Barclays PLC lifted its holdings in shares of Sight Sciences by 317.4% in the third quarter. Barclays PLC now owns 50,300 shares of the company's stock valued at $317,000 after purchasing an additional 38,248 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Sight Sciences by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock valued at $60,000 after purchasing an additional 5,781 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Sight Sciences by 10.7% in the fourth quarter. American Century Companies Inc. now owns 51,564 shares of the company's stock valued at $188,000 after purchasing an additional 4,964 shares in the last quarter. Institutional investors own 55.51% of the company's stock.

Sight Sciences Stock Down 7.9%

SGHT stock traded down $0.28 during midday trading on Monday, hitting $3.27. The company's stock had a trading volume of 173,485 shares, compared to its average volume of 214,493. The company has a market cap of $169.05 million, a PE ratio of -3.21 and a beta of 2.41. Sight Sciences, Inc. has a 12 month low of $2.03 and a 12 month high of $8.45. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The firm's 50-day moving average is $2.77 and its 200-day moving average is $3.15.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. The firm had revenue of $17.51 million during the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. On average, equities research analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Paul Badawi sold 24,174 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the sale, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. The trade was a 0.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Manohar K. Raheja purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average price of $2.73 per share, with a total value of $27,300.00. Following the acquisition, the executive vice president now directly owns 145,000 shares of the company's stock, valued at $395,850. This trade represents a 7.41% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 35,196 shares of company stock worth $81,001. Corporate insiders own 30.90% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Stifel Nicolaus dropped their target price on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Piper Sandler dropped their price objective on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a research note on Thursday, March 6th. UBS Group dropped their price objective on Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a research note on Monday, January 27th. Finally, Lake Street Capital lifted their price objective on Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a research note on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $3.92.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.